Xarelto for the Prevention of Stroke and Noncentral Nervous Systemic Embolism in Non-valvular Atrial Fibrillation With REnal Impairment in Taiwanese Population
Latest Information Update: 01 Jan 2024
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions
- Acronyms XARETO
- Sponsors Bayer
Most Recent Events
- 29 Jan 2023 Status changed from active, no longer recruiting to completed.
- 28 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2022 Planned primary completion date changed from 31 Jul 2022 to 15 Nov 2022.